Risk of post-stroke pneumonia with proton pump inhibitors, H 2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study

Tae Jin Song, Jinkwon Kim

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Stroke patients are at high risk of developing pneumonia, which is major cause of post-stroke mortality. Proton pump inhibitors and H 2 receptor antagonists are anti-ulcer drugs, which may predispose to the development of pneumonia by suppression of the gastric acid with bactericidal activity. Unlike proton pump inhibitors and H 2 receptor antagonists, mucoprotective agents have gastroprotective effects with no or less anti-acid property. We aimed to investigate effects of the acid-suppressive medications (proton pump inhibitors and H 2 receptor antagonists) and mucoprotective agents on risk for post-stroke pneumonia using the National Health Insurance Service-National Sample Cohort in Korea. This retrospective cohort study included 8,319 patients with acute ischemic stroke. Use of proton pump inhibitors, H 2 receptor antagonists, and mucoprotective agents (rebamipide, teprenone, irsogladine, ecabet, polaprezinc, sofalcone, sucralfate, and misoprostol) after stroke were determined based on the prescription records, which were treated as time-dependent variables. Primary outcome was the development of post-stroke pneumonia. During the mean follow-up period of 3.95 years after stroke, 2,035 (24.5%) patients had pneumonia. In the multivariate time-dependent Cox regression analyses (adjusted hazard ratio [95% confidence interval]), there was significantly increased risk for pneumonia with use of proton pump inhibitors (1.56 [1.24–1.96]) and H 2 receptor antagonists (1.40 [1.25–1.58]). In contrast to the proton pump inhibitors and H 2 receptor antagonists, use of mucoprotective agents did not significantly increase the risk for pneumonia (0.89 [0.78–1.01]). In conclusion, the treatment with proton pump inhibitors and H 2 receptor antagonists was associated with increased risk for pneumonia in stroke patients. Clinicians should use caution in prescribing the acid-suppressive medications for the stroke patients at great risk for pneumonia.

Original languageEnglish
Article numbere0216750
JournalPLoS ONE
Volume14
Issue number5
DOIs
StatePublished - May 2019

Bibliographical note

Funding Information:
This work was supported by grants (NRF-2017R1D1A1B03033382, 2018R1D1A1B07040959) of the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study used NHIS-NSC data (NHIS-2018-2-153) made by NHIS.

Publisher Copyright:
© 2019 Song, Kim. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Fingerprint

Dive into the research topics of 'Risk of post-stroke pneumonia with proton pump inhibitors, H 2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study'. Together they form a unique fingerprint.

Cite this